84.18

0.60% -0.51

Pre-market: 84.42 0.24 +0.29%

Blueprint Medicines Corp (BPMC)

Overview News Price History Option Chain Financials Why BPMC Down? Discussions Forecast

Blueprint Medicines Corp stock is traded at $84.18, with a volume of 934.03K. It is down -0.60% in the last 24 hours and down -5.12% over the past month. Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Previous Close:

$84.69

Open:

$84.01

24h Volume:

934.03K

Relative Volume:

0.91

Market Cap:

$5.32B

Revenue:

$434.41M

Net Income/Loss:

$-128.05M

P/E Ratio:

-39.90

EPS:

-2.11

Net Cash Flow:

$-250.52M

1W Performance:

+2.00%

1M Performance:

-5.12%

6M Performance:

-1.67%

1Y Performance:

-3.07%

1-Day Range:

$83.60

$86.10

1-Week Range:

$78.66

$86.10

52-Week Range:

$73.04

$121.90

Blueprint Medicines Corp Stock (BPMC) Company Profile

Name

Blueprint Medicines Corp

Sector

Healthcare (1155)

Industry

Biotechnology (677)

Phone

617-374-7580

Address

45 SIDNEY STREET, CAMBRIDGE, MA

Employee

655

Twitter

@BlueprintMeds

Next Earnings Date

2024-10-30

Latest SEC Filings

BPMC's Discussions on Twitter

Compare BPMC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BPMC Blueprint Medicines Corp	84.18	5.32B	434.41M	-128.05M	-250.52M	-2.11
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-20-25	Resumed	Morgan Stanley	Equal-Weight
Mar-18-25	Initiated	Wolfe Research	Outperform
Mar-17-25	Initiated	Jefferies	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Nov-14-24	Initiated	JP Morgan	Overweight
Oct-24-24	Initiated	UBS	Neutral
May-14-24	Initiated	Stephens	Overweight
May-06-24	Upgrade	Leerink Partners	Underperform → Market Perform
Oct-27-23	Upgrade	Oppenheimer	Perform → Outperform
Aug-21-23	Reiterated	Needham	Buy
Jul-31-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jun-05-23	Downgrade	SVB Securities	Market Perform → Underperform
Jan-03-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Needham	Buy
Nov-02-22	Downgrade	Oppenheimer	Outperform → Perform
Sep-14-22	Initiated	Berenberg	Buy
Jul-08-22	Initiated	Oppenheimer	Outperform
Jun-27-22	Initiated	Wells Fargo	Underweight
Jun-10-22	Downgrade	Citigroup	Neutral → Sell
Jun-01-22	Upgrade	Jefferies	Hold → Buy
Mar-01-22	Initiated	Citigroup	Neutral
Feb-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jan-25-22	Upgrade	Stifel	Hold → Buy
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Sep-30-21	Resumed	Stifel	Hold
Jun-04-21	Resumed	Robert W. Baird	Outperform
Mar-31-21	Initiated	Credit Suisse	Neutral
Dec-03-20	Initiated	Stifel	Hold
Nov-02-20	Reiterated	H.C. Wainwright	Buy
Nov-02-20	Downgrade	Jefferies	Buy → Hold
Oct-30-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-15-20	Reiterated	H.C. Wainwright	Buy
May-05-20	Initiated	Barclays	Equal Weight
Mar-17-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-28-20	Initiated	BMO Capital Markets	Market Perform
Jan-27-20	Initiated	BMO Capital Markets	Market Perform
Nov-06-19	Upgrade	Raymond James	Outperform → Strong Buy
Oct-22-19	Initiated	JMP Securities	Mkt Outperform
Oct-03-19	Initiated	H.C. Wainwright	Buy
Sep-12-19	Upgrade	Raymond James	Mkt Perform → Outperform
Aug-29-19	Initiated	Piper Jaffray	Neutral
Aug-15-19	Resumed	Raymond James	Mkt Perform
Jul-18-19	Initiated	Deutsche Bank	Buy
May-23-19	Resumed	Goldman	Buy
Apr-03-19	Initiated	Morgan Stanley	Overweight
Sep-25-18	Initiated	Leerink Partners	Outperform
Dec-11-17	Reiterated	Goldman	Buy

View All

Blueprint Medicines Corp Stock (BPMC) Latest News

Apr 21, 2025

Wedbush Reaffirms “Outperform” Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World

Apr 18, 2025

Apr 17, 2025

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Blueprint Medicines (BPMC) - The Globe and Mail

Apr 17, 2025

Apr 15, 2025

Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Apr 15, 2025

Apr 13, 2025

Franklin Resources Inc. Lowers Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World

Apr 13, 2025

O Shaughnessy Asset Management LLC Reduces Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World

Apr 13, 2025

Blueprint Medicines' (BPMC) Buy Rating Reiterated at Needham & Company LLC - MarketBeat

Apr 13, 2025

Apr 11, 2025